Organizations reacted this week to news that CMS is raising Part B premiums with a variety of opinions, as CMS blamed rising drug prices for the increase.
Organizations reacted this week to news that CMS is raising Part B premiums with a variety of opinions, as CMS blamed rising drug prices for the increase.
“The increase in the Part B premiums and deductible is largely due to rising spending on physician-administered drugs,” CMS said last week. “These higher costs have a ripple effect and result in higher Part B premiums and deductible.”
Yearly adjustments to all parts of Medicare are made according to the Social Security Act. For 2020, the new costs for most beneficiaries are:
The majority of beneficiaries (70%) pay the standard amount; a minority of upper-income beneficiaries pay more. However, the standard increase for Part B in 2019 was much more modest ($1.50); in addition, the CMS announcement follows a small (1.6%) cost-of-living adjustment to 2020 benefits in 2020, which was pointed out by the AARP.
“This announcement is another clear example of how prescription drug prices are rising faster than inflation and how drug company greed is hurting seniors. With Medicare premiums increasing nearly 7% while Social Security payments will increase less than 2%, Congress needs to immediately act to lower prescription drug prices,” said Nancy LeaMond, AARP’s executive vice president and chief advocacy and engagement officer.
The Biosimilars Forum also chimed in, criticizing Congress and the administration for not doing enough to increase access to biosimilars, saying that the 9 biosimilars available in Part B cost about 30% less than the reference products. They said that beneficiaries “are often denied access to or unaware a lower-cost option exists due to misaligned incentives that favor the higher-cost product.”
The forum, which represents 8 biosimilar developers, has been advocating for ending out-of-pocket cost for biosimilars, saying such a move could save as much as $3.3 billion and increase access. In the statement, the forum highlighted 3 bipartisan bills that have been introduced in Congress:
The BIOSIM act is also included in the drug pricing plan preferred by House Speaker Nancy Pelosi, D-California, although it will not be considered by the Senate, even as seriously ill beneficiaries continue to struggle with healthcare costs. Meanwhile, President Trump is said to prefer a bipartisan Senate bill, but that does not have unanimous Republican support either.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.